-logo-1200x675.png){kind=logo}
BioGaia AB (publ) (OTCMKTS:BIOGY – Get Free Report) is expected to announce its resultson Thursday, October 22nd. Analysts expect BioGaia AB (publ) to post earnings of $0.9040 per share and revenue of $383.54 million for the quarter.
BioGaia AB (publ) Price Performance
Shares of OTCMKTS:BIOGY opened at $12.45 on Wednesday. BioGaia AB has a 12 month low of $9.64 and a 12 month high of $12.45. The stock’s 50 day moving average price is $12.43 and its 200 day moving average price is $11.59.
BioGaia AB (publ) Company Profile
BioGaia AB (publ) is a Swedish health-care company that develops, markets and sells probiotic products. Its portfolio is based primarily on scientifically documented strains of Limosilactobacillus reuteri, formerly known as Lactobacillus reuteri, and is intended to support digestive and immune health.
The company offers probiotic products for infants, children and adults, including oral drops, tablets, chewable products and other formulations. Its brands and product lines include BioGaia Protectis for digestive health, BioGaia Gastrus for gastrointestinal support and BioGaia Prodentis for oral health.
Further Reading
- Five stocks we like better than BioGaia AB (publ)
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
- Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling?
- Halliburton Gains Traction: Multiyear Upcycle Ahead
- Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge
Receive News & Ratings for BioGaia AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioGaia AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
